Nomos pulls IPO (initial public offering) because of market conditions:
This article was originally published in Clinica
Nomos, which develops and markets products aimed at improving the safety and effectiveness of radiation treatment of cancerous tumours, has withdrawn its IPO because of current market conditions. The Sewickly, Pennsylvania-based company says its business is healthy, with growing revenues, is profitable and has a positive cash flow. It will re-evaluate its position when market conditions improve, said president and CEO John Manzetti.